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Introduction
Platelet/endothelial cell adhesion molecule-1 (PECAM-
1) is a 130-kDa glycoprotein belonging to the Ig super-
family of cell adhesion molecules (1). PECAM-1 is wide-
ly expressed on endothelial cells (2, 3), circulating
platelets, monocytes, granulocytes, subsets of lympho-
cytes, and bone marrow hematopoietic cells (4–7). On
continuous endothelial cell monolayers, PECAM-1
expression is concentrated at areas of cell-cell contact
(2, 3). As a cell adhesion molecule, PECAM-1 is capable
of mediating homophilic binding (8–10) as well as het-
erophilic binding (11, 12).
PECAM-1 is thought to be involved in the
transendothelial migration of leukocytes during their
extravasation to sites of inflammation. It is an ideal
candidate molecule for this role due to (a) its expres-
sion on most circulating leukocytes as well as the
endothelial cells lining the vasculature; (b) its localiza-
tion at endothelial cell-cell junctions, the site of leuko-
cyte diapedesis; and (c) its ability to mediate
homophilic as well as both heterophilic and heterotyp-
ic adhesion. In vitro studies using PECAM-1–blocking
reagents have demonstrated that PECAM-1 plays a role
in transmigration of leukocytes in vitro (13–15) and in
animal models of inflammation (16–19). However, it
has also been demonstrated that the involvement of
PECAM-1 is selective for leukocyte migration elicited
by specific inflammatory stimuli (18). The expression
of PECAM-1 by transmigrating leukocytes does not
appear to be obligatory, as anti-PECAM blocking anti-
bodies do not inhibit transmigration completely. In
addition, a T cell population depleted of PECAM-1+
cells was able to migrate across human umbilical vein
endothelial cell monolayers (20). In PECAM-1–defi-
cient mice (21) there is a transient delay in polymor-
phonuclear leukocyte trafficking across the suben-
dothelial basal lamina during acute inflammation, but
normal numbers of migrated cells are recovered from
the inflammatory site. Additionally, PECAM-1–defi-
cient (PECAM-KO) mice are able to mount a normal
cutaneous hypersensitivity response (21).
PECAM-1 may also play an indirect role in leukocyte
extravasation. Numerous cellular “activation” stimuli
induce the phosphorylation of the PECAM-1 cytoplas-
mic domain (22–26), which in turn can interact with
phosphatases (27–29) and kinases (26, 30) to mediate
a number of intracellular signaling events. Engagement
of PECAM-1 signals increases in β1 and β2 integrin
affinity (15, 31–34), leading to firm adhesion of circu-
lating leukocytes to vascular endothelium during
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Platelet/endothelial cell adhesion molecule-1 (PECAM-1, CD31), a 130-kDa glycoprotein member of
the Ig superfamily of transmembrane proteins, is expressed on endothelial cells, platelets, and sub-
sets of leukocytes. It functions as a cell adhesion molecule as well as a scaffolding molecule capable
of modulating cellular signaling pathways. In this study, using PECAM-1–deficient (KO) mice, as well
as cells derived from these mice, we demonstrate that the absence of PECAM-1 expression is associ-
ated with an early onset of clinical symptoms during experimental autoimmune encephalomyelitis
(EAE), a mouse model for the human autoimmune disease multiple sclerosis. During EAE, mononu-
clear cell extravasation and infiltration of the CNS occur at earlier time points in PECAM-KO mice
than in wild-type mice. In vitro, T lymphocyte transendothelial migration across PECAM-KO
endothelial cells is enhanced, regardless of expression of PECAM-1 on transmigrating T cells. Addi-
tionally, cultured PECAM-KO endothelial cells exhibit prolonged permeability changes in response
to histamine treatment compared with PECAM-1–reconstituted endothelial cells. Lastly, we demon-
strate an exaggerated and prolonged CNS vascular permeability during the development of EAE and
a delay in restoration of dermal vascular integrity following histamine challenge in PECAM-KO mice.
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extravasation (35). Both migration of leukocytes and
signaling of effector functions of those cells are essen-
tial components of an immune response, and there is a
growing body of evidence to suggest that PECAM-1 is
involved in modulating cellular behavior of leukocytes
(25, 34, 36, 37).
Here, we examine the contribution of PECAM-1
expression on endothelium and antigen-specific T cells
to a specific model of inflammation, experimental
autoimmune encephalomyelitis (EAE). EAE is an
autoimmune inflammatory disease of the CNS in mice,
used as a model to study the human demyelinating dis-
ease multiple sclerosis (38). Progression of EAE is regu-
lated at many points during the course of disease,
including activation of autoimmune T cells, T cell adhe-
sion to blood vessel endothelium, transmigration across
the blood-brain barrier, establishment of an autoim-
mune response in the CNS, recruitment of inflamma-
tory cells to the CNS, and maintenance of CNS inflam-
mation. Adhesion or signaling mediated by PECAM-1
could potentially play a role in any of these processes.
Administration of PECAM-1 antibodies had no effect
on the course of EAE in a rat model (39). However, the
generation of the PECAM-KO mouse (21) along with
the development of the myelin oligodendrocyte glyco-
protein (MOG) immunization model for chronic EAE
in C57BL/6 mice (40) provided us with a model in
which to study the clinical progression of EAE in the
complete absence of PECAM-1. In this report, we
demonstrate that the absence of PECAM-1 expression
in mice results in an early onset of clinical symptoms
during EAE, associated with an increased leukocyte
migration across the blood-brain barrier. We also
demonstrate an impaired ability to restore vascular
integrity after alteration of the endothelium in
PECAM-KO mice or of cultured PECAM-KO endothe-
lial cells. The resulting increased and prolonged vascu-
lar permeability could potentially lead to enhanced
transendothelial migration of leukocytes and early
onset of CNS inflammation during EAE.
Methods
Antibodies and reagents. Monoclonal anti–PECAM-1
(MEC13.3), VE-cadherin (11D4.1), CD4 (RM4-5),
CD8 (53-6.7), Mac-1 (M1/70), B220 (RA3-6B2), and
Gr-1 (Ly-6G, RB6-8 C5) were purchased from
PharMingen (San Diego, California, USA). Fluo-
rophore-conjugated secondary antibodies were pur-
chased from Jackson ImmunoResearch Laboratories
Inc. (West Grove, Pennsylvania, USA). Rat anti-mouse
mAb’s used at the Max-Planck-Institute were purified
from serum-free hybridoma supernatants.
Anti–PECAM-1 (MEC13.3 or GC.51), anti–ICAM-1
(25ZC7), anti–ICAM-2 (3C4), anti–VCAM-1 (9B5),
and anti-human CD44 (9B5) as an isotype-matched
control were previously described (41, 42). MOG pep-
tide 35-55 (MEVGWYRSPFSRVVHLYRNGK) of rat
origin was synthesized by the W.M. Keck Biotechnol-
ogy Resource Center at Yale University.
Cells and cell culture
Antigen-specific T cell lines. MOG-specific T cells were
derived from C57BL/6 mice immunized with purified
MOG peptide 35-55 (300 µg per mouse) emulsified 1:1
in CFA (Difco Laboratories, Detroit, Michigan, USA).
Ten days later, cells were harvested from draining
lymph nodes and cultured. Expression of PECAM-1
and T cell markers was analyzed by flow cytometry. The
derivation and maintenance of the proteolipid pro-
tein–specific (PLP-specific) T cell lines were described
in detail previously (42, 43).
Microvascular endothelial cells. Microvascular endothe-
lial cells used in Figure 3 were harvested and cultured
according to the method described by Plendl et al. (41).
Endothelial cells were isolated by FACS sorting on
PECAM-1/VE-cadherin double-positive cells (wild-type
[WT]) or VE-cadherin–positive cells (KO) and used for
experiments from passages 2 to 4.
Endothelioma cell lines. PECAM-KO endothelioma cell
lines bEnd.PECAM-1.2, mlEnd.PECAM-1.1, and
luEnd.PECAM-1.1 were established by retroviral trans-
duction of primary endothelial cell culture with the
polyoma virus middle T-oncogene as described (44, 45).
The endothelioma cell lines retained endothelial mor-
phology and showed contact inhibition upon conflu-
ence. The wild-type line bEnd.WT derived from mouse
brain endothelium was used as a control because, with
the exception of PECAM-1, the cell surface expression
levels of adhesion molecules, most importantly 
ICAM-1 and ICAM-2, were similar to those of the
PECAM-1–deficient endothelioma cell lines as deter-
mined by FACS analysis. Endothelioma cells were used
for experiments from passages 8 to 25.
Retroviral infection of endothelioma cells. A full-length
murine PECAM-1 cDNA fragment was isolated from a
pcDNA3 plasmid clone (45) (courtesy of Beat Imhof,
University of Geneva, Geneva, Switzerland) and ligated
into pSL1190 (Pharmacia Biotech, Cambridge, United
Kingdom). The full-length PECAM-1 fragment was
released and ligated into pBABE puromycin (46). The
resulting construct was transfected into the retrovirus
packaging cell line GP+E86, and stable clones were
selected in the presence of puromycin as described
before (44). Supernatant of GP+E86 PECAM-1 trans-
fectants supplemented with 8 µg/ml Polybrene (Sigma-
Aldrich Co., St. Louis, Missouri, USA) was used to
transduce the PECAM-1–deficient endotheliomas with
full length PECAM-1. Clones were grown to passage 5
and expression of PECAM-1 in retransfected cells was
analyzed by FACS analysis and immunofluorescence.
The PECAM-1–deficient endothelioma line
luEnd.PECAM-1.1-clone 9 and its respective retrans-
fected line luEnd.PPA2, termed PECAM-KO and
PECAM-RC (reconstituted with PECAM-1), respective-
ly, were used in this study.
Mice. C57BL/6 WT mice were purchased from
Charles River Laboratories (Wilmington, Massachu-
setts, USA). PECAM-1–deficient (PECAM-KO) mice
were generated and analyzed as described by Duncan 
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et al. (21). Before breeding pairs were sent to Yale Uni-
versity, the PECAM-1–deficient mice were backcrossed
onto C57BL/6 eight times. At Yale University the
PECAM-KO mice were backcrossed onto C57BL/6 sev-
eral more times before experimentation was begun.
Hematopoietic precursor engraftment of WT and
PECAM-KO mice was performed as described (47).
Induction of EAE with MOG peptide. EAE was induced
using a MOG immunization protocol in C57BL/6 mice,
according to the procedure previously described (40).
The mice were monitored daily and graded for clinical
symptoms of EAE. Some mice were sacrificed at indicat-
ed times, and CNS tissues were prepared for slides. This
MOG immunization protocol in C57BL/6 mice induces
chronic, nonremitting EAE clinical symptoms (40).
Adoptive transfer of EAE with MOG peptide–specific T cells
derived from WT and PECAM-KO C57BL/6 mice. EAE was
induced using an adoptive transfer protocol in
C57BL/6 mice according to the previously published
procedure (40). The mice were monitored daily and
graded for clinical symptoms of EAE (48, 49).
Isolation of leukocytes from CNS. To isolate lymphocytes
and monocytes, CNS tissue was dissected, homoge-
nized, incubated with 1 mg/ml collagenase II (Sigma-
Aldrich Co.), and run over a gradient of PBS-buffered
Percoll (Amersham Pharmacia Biotech, Piscataway,
New Jersey, USA). Isolated cells were analyzed by flow
cytometry. For detection of intracellular cytokine pro-
duction, cells were isolated as above and cultured with
the protein transport inhibitors GolgiStop (0.67 µl/ml;
for IFN-γ) or GolgiPlug (1 µl/ml; for TNF-α). Cells were
then resuspended and stained for CD4 or Mac-1 as
above. Next, cells were fixed and permeabilized with
Cytofix/Cytoperm, stained for IFN-γ or TNF-α, and
analyzed by flow cytometry. GolgiStop, GolgiPlug, and
Cytofix/Cytoperm were purchased from PharMingen.
T cell priming assay. WT and PECAM-KO mice were
immunized subcutaneously in the tail with 50 µl of a
1:1 MOG/CFA emulsion at the same concentrations as
used for EAE studies. After 10 days, cells were harvested
from draining lymph nodes. Triplicate wells of a 96-well
microtiter plate were prepared with 2 × 105 lymph node
cells in 200 µl of Bruff ’s medium containing 10% FCS,
and varying concentrations of MOG peptide antigen
(12.5–50 µg/ml). After 48 hours in culture, each sample
was pulsed with 1 µCi 3H-thymidine, incubated for an
additional 16 hours, and collected using a Skatron 12
Channel Combi Cell Harvester (Skatron Instruments,
Sterling, Virginia, USA), and proliferative response to
MOG peptide antigen was measured in cpm of β-radia-
tion incorporated into the proliferating cell cultures.
T cell transendothelial migration assays. A Biocoat tissue
culture insert system was used (Becton Dickinson Lab-
ware, Franklin Lakes, New Jersey, USA) to measure in
vitro transmigration of T cells through monolayers of
WT and PECAM-KO microvascular endothelial cells
(Figure 3), as previously described (48, 49). Transmi-
gration assays in Figure 4 were performed exactly as
previously described (42, 44).
In vitro endothelial permeability assays. To measure perme-
ability changes of endothelial cells in vitro, endothelioma
lines were cultured to confluence on Biocoat tissue cul-
ture inserts placed in tissue culture wells (Becton Dick-
inson Labware). Culture media were replaced with color-
less HBSS. In control samples, 20 µl of 0.5% (wt/vol)
Evans blue dye was added to the upper compartment to
ensure that the endothelial layers were impermeable to
this dye. Experimental wells were treated with histamine
(3.2 × 10–5 M; Sigma-Aldrich Co.), and 20 µl dye was
added to the upper compartments at various time points
following histamine exposure. The liquid was collected
from the lower wells after 2 minutes and measured by
spectrophotometric absorbance at 650 nm.
In vivo endothelial permeability assays. At various days fol-
lowing EAE induction, mice were injected retro-orbital-
ly with 0.5% (wt/vol) Evans blue dye in PBS (4 µl/g of
body weight) (50). After 1 hour, mice were anesthetized
and perfused via the left ventricle with cold PBS, and
brains were removed. Dye was extracted from the CNS
tissue for 3 days in formamide (5 µl/mg of tissue) at
room temperature. Extracted dye concentration was
determined by measuring the absorbance at 650 nm.
The blood-brain barrier permeability index (PI) was cal-
culated by dividing the OD value for each sample by the
average OD value of tissue from three mice that had not
received Evans blue dye. Skin vessel permeability of each
mouse was determined similarly in Figure 6b.
In Figure 6c, skin vessel permeability was determined
following intradermal histamine challenge, according to
a modification of the Miles assay (51). Mice were given
an intradermal injection of histamine (3 µg in 50 µl PBS)
in one flank and a 50-µl injection of PBS in the opposite
flank. At indicated time points after histamine injection,
Evans blue dye was injected retro-orbitally as above. Mice
were sacrificed 5 minutes after dye injection, and skin
was harvested. Dye was extracted in formamide as above,
and absorbance at 650 nm was measured. The PI for
each mouse was determined by dividing the OD value
obtained from the histamine-injected flank skin by the
value obtained from the PBS-injected flank skin.
In Figure 6d, mice were first injected retro-orbitally with
Evans blue as above. After 45 minutes, histamine and PBS
were injected intradermally as above. At 5 and 15 minutes
after histamine injection, mice were sacrificed, skin was
dissected, dye was extracted in formamide (10 µl/mg of tis-
sue) at 56°C for 24 hours, and PI was calculated as above.
Statistics. Results were analyzed using two-way
ANOVA, with two between-group factors (SAS 8.2 soft-
ware; SAS Institute Inc., Cary, North Carolina, USA)
(Figures 3 and 4), or using N-way ANOVA and an all-
pairwise multiple comparison procedure (Student-
Newman-Keuls method) (SPSS Science, Chicago, Illi-
nois, USA) (Figures 1, 2, 5, and 6).
Results
PECAM-KO mice exhibit early onset of EAE and early
inflammatory cell migration into CNS. To examine the
role of PECAM-1 in MOG-induced EAE, C57BL/6 WT
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and PECAM-KO mice were immunized with MOG
peptide antigen and monitored daily for clinical symp-
toms of EAE (Figure 1a). The PECAM-KO mice were
susceptible to MOG-induced EAE and developed clin-
ical disease symptoms significantly earlier than did
WT mice. The differences in the mean values among
the groups (WT and KO) are greater than would be
expected by chance (F = 24.17, P < 2.23 × 10–30). An all-
pairwise multiple comparison procedure resulted in
significant differences between the two groups from
days 12 through 22. By day 24 the average severity of
disease scores was comparable between WT and
PECAM-KO mice. Both groups of mice exhibited
chronic disease, which is typical of MOG-induced EAE
in the C57BL/6 model (40).
To determine the extent of inflammatory cell traf-
ficking into the CNS parenchyma, brain tissues of WT
and PECAM-KO mice were examined (Figure 1, b–j). In
comparison to WT mice, perivascular mononuclear cell
infiltrates were noted earlier in PECAM-KO tissues.
Specifically, at 4 days after immunization neither WT
nor PECAM-KO mice exhibited appreciable perivascu-
lar or parenchymal invasion of inflammatory cells into
the CNS (Figure 1, b and c). At day 8, the brains of WT
mice were mostly devoid of inflammatory infiltrates,
while substantial perivascular cuffing of mononuclear
cells was observed in the brains of PECAM-KO mice
(Figure 1, d and e). By day 20, brains of both WT and
PECAM-KO mice exhibited modest meningeal and
submeningeal perivascular infiltrates (Figure 1, f and
g). However, brains of PECAM-KO mice exhibited more
robust invasion around larger, deeper vessels compared
with WT mice, corresponding to significantly higher
disease severity scores (Figure 1, h and i). Lytic foci were
also apparent in brains of PECAM-KO mice (Figure 1j).
At later time points, when the average clinical disease
scores were similar for both groups of mice (days
24–30), the inflammatory infiltrates were similar to
those illustrated in Figure 1, i and j, and were indistin-
guishable from each other (data not shown).
Leukocytes were isolated from the CNS of WT and
PECAM-KO mice in the early stages of EAE to deter-
mine the composition of invading cells. In comparison
to WT mice, increased numbers of total leukocytes,
CD4+ and CD8+ T cells, B cells, total macrophages,
TNF-α–producing (activated) macrophages, and neu-
trophils were present in the CNS of PECAM-KO mice
(Table 1). Increases in MOG-specific CD4+ T cells were
also seen earlier and in greater numbers in the CNS of
PECAM-KO mice (data not shown).
The increased presence of inflammatory cells in the
brain tissue of PECAM-KO mice may be due to either
an enhanced initial immune response to antigen or an
increased ability of inflammatory cells to transmigrate
across the blood-brain barrier. Because PECAM-1 pos-
sesses the ability to modulate signal transduction, the
initial response of MOG-specific T cells to antigen may
be increased. Following immunization with MOG pep-
tide, cells were isolated from draining lymph nodes.
There is no significant difference between WT and
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Figure 1
PECAM-KO mice exhibit early incidence of EAE and earlier mononu-
clear cell infiltration of CNS parenchyma. (a) Average disease scores
of WT and PECAM-KO mice calculated daily following induction of
disease with MOG peptide. Disease symptoms manifested earlier in
the PECAM-KO mice than in WT mice. (b–j) Representative hema-
toxylin and eosin–stained sections of cerebral cortex taken from the
brains of WT (b, d, f, and h) and PECAM-KO mice (c, e, g, i, and j)
at 4 days (b and c), 8 days (d and e), and 20 days (f–j) following EAE
induction. PECAM-KO animals exhibited more intense perivascular
(i) and parenchymal (j) infiltrates than their WT counterparts (h),
which correlated with the difference in clinical disease scores noted
at this time (a). Arrows indicate perivascular mononuclear cells. V,
vessel; M, meninges. Scale bar = 50 µm.
Table 1
PECAM-KO mice have more leukocytes in the CNS early in EAE
GroupA Total CNS CD4+ CD8+ Macrophages B cells Neutrophils MOG-activated
leukocytes macrophages
WT 1.47 × 106 0.75 × 105 0.33 × 105 1.76 × 105 1.29 × 105 1.00 × 105 2.24 × 105
SEM 0.26 × 106 0.49 × 105 0.79 × 104 0.37 × 105 0.62 × 105 0.28 × 105 0.73 × 105
PECAM-KO 4.17 × 106 5.45 × 105 2.96 × 105 8.51 × 105 2.81 × 105 3.30 × 105 1.17 × 106
SEM 0.81 × 106 0.55 × 105 1.64 × 105 2.31 × 105 0.50 × 105 0.67 × 105 0.27 × 104
Significance P < 0.03 P < 0.003 P < 0.18 P < 0.04 P < 0.13
Inflammatory cell infiltration of the CNS during EAE is increased in PECAM-KO mice. Shown are numbers of leukocytes isolated from the CNS (brain plus
spinal cord) of WT and PECAM-KO mice, during the early stages of EAE. AEach number is an average of three experiments, except for neutrophils and acti-
vated macrophages, which are averages of two experiments.
PECAM-KO lymph node cells in their ability to prolif-
erate in response to a range of concentrations of MOG
peptide antigen (Figure 2a). In addition, we have
demonstrated, using adoptive transfer techniques (47,
48), an earlier onset of EAE in KO mice than in WT
mice, regardless of whether the mice were injected
intravenously with antigen-specific (MOG) WT or
PECAM-KO T lymphocytes (Figure 2b). The differ-
ences in the mean values among the animal groups
(WT and KO mice) are greater than would be expected
by chance (F = 3.85, P < 7.1 × 10-9). An all-pairwise mul-
tiple comparison procedure resulted in significant dif-
ferences between the two groups from days 13 through
16. No differences were noted in KO mice given WT or
KO MOG-specific T lymphocytes. Further, using WT
mice lethally irradiated and engrafted with PECAM-KO
marrow and KO mice lethally irradiated and engrafted
with WT marrow (47), we demonstrated an earlier dis-
ease onset of EAE in the KO mice following direct
immunization with MOG peptides (Figure 2c). The dif-
ferences in the mean values among the marrow recipi-
ent groups (WT mice engrafted with KO marrow and
KO mice engrafted with WT marrow) are greater than
would be expected by chance (F = 7.9, P < 3.1 × 10–22).
An all-pairwise multiple comparison procedure result-
ed in significant differences between the two groups
from days 13 through 17. These studies support the
concept that while EAE is a T cell–mediated disease
process, it is dependent, in part, upon the presence or
absence of endothelial PECAM-1. Therefore, we inves-
tigated a second possibility that transendothelial
migration of immune system cells may play a role in
the early onset of EAE in the PECAM-KO mice.
Endothelial cells derived from PECAM-KO mice support
enhanced in vitro transendothelial migration of T cells. We per-
formed in vitro transmigration assays using low-passage
endothelial cells and MOG-specific T cells derived from
WT and PECAM-KO mice (Figure 3, a–c). Interestingly,
endothelial cells derived from PECAM-KO mice sup-
ported a significantly higher level of T cell transmigra-
tion (∼42%) compared with WT endothelial cells (∼31%),
regardless of expression of PECAM-1 on the T cells.
Two-way ANOVA, with two between-group factors,
revealed a significant main effect for the endothelial cell
type (WT versus KO) [F1,28 = 113.02, P < 0.001]. The
main effect for T cell type (WT versus KO) proved to be
insignificant, [F1,28 = 0.04, P = 0.85], as did the interac-
tion between endothelial cell type (WT versus KO) and
T cell type (WT versus KO) [F1,28 = 0.10, P = 0.76].
In addition, we performed adhesion and transmi-
gration assays using immortalized endothelioma cell
lines derived from brain microvasculature of WT and
PECAM-KO mice (Figure 4a) and lung microvascula-
ture of PECAM-KO mice, and the same cells reconsti-
tuted with PECAM-1 (PECAM-RC) (Figure 4b). We
found the level of adhesion of MOG-specific T cells
derived from WT (Figure 4c) and PECAM-KO (Figure
4e) animals to these four endothelioma lines indistin-
guishable (Figure 4, c and e). Analyses using two-way
ANOVA revealed no significant differences between
groups. In contrast, migration of T cells across
PECAM-KO endotheliomas derived from brain
(bEnd.PECAM-1.2) and lung (luEnd.PECAM-1.1) was
significantly increased in comparison with transmi-
gration across WT endothelioma monolayers derived
from brain (bEnd.WT) and KO endothelioma mono-
layers derived from lung (luEnd.PECAM-1.1) that
were transfected and stably expressing PECAM-1
(PECAM-RC) (Figure 4, d and f). These endothelioma
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Figure 2
Antigen-specific T lymphocytes derived from PECAM-KO and WT
mice are indistinguishable in in vitro priming assays (a) and in vivo
adoptive transfer (b) and marrow engraftment assays (c). (a) In
vitro priming assay illustrating that the proliferation of in vivo MOG
peptide–primed T lymphocytes harvested from the draining lymph
nodes of PECAM-KO and WT mice is indistinguishable. n = 5. Ver-
tical lines represent standard deviations. (b) Adoptive transfer study
illustrating that the time of onset of EAE correlates with the pres-
ence or absence of endothelial PECAM-1. KO → WT = antigen-spe-
cific PECAM-1–deficient T lymphocytes adoptively transferred into
a WT recipient. WT → KO = antigen-specific PECAM-1–positive 
T lymphocytes adoptively transferred into a PECAM-1–deficient
recipient. KO → KO = antigen-specific PECAM-1–deficient T lym-
phocytes adoptively transferred into a PECAM-1–deficient recipient.
n = 4. (c) PECAM-KO mice engrafted with WT marrow precursors
(WT → KO), but not WT mice engrafted with PECAM-KO marrow
precursors (KO → WT), exhibit an early incidence of EAE. This study
also illustrates that the time of onset of EAE correlates with the pres-
ence or absence of endothelial PECAM-1. This graph represents an
average of one of three independent experiments, each having
groups of three WT → KO and KO → WT mice.
lines express equivalent levels of VE-cadherin, 
ICAM-1, ICAM-2 (not shown), and VCAM-1 (not
shown), but only WT and PECAM-RC cells express
PECAM-1 (Figure 4, a and b). In these transmigration
assays the percent transmigration was also noted to be
dependent upon PECAM-1 expression on the MOG-
specific T lymphocyte clones, with the WT T lympho-
cytes exhibiting a greater percent transmigration than
the KO T lymphocytes (Figure 4, compare d with f).
Two-way ANOVA, with two between-group factors,
revealed a significant main effect for endothelial cell
type (brain WT versus KO) [F1,13 = 23.56, P = 0.0007]
and a significant main effect for T cell type (WT ver-
sus KO) [F1,13 = 11.77, P = 0.0064]. The interaction
between endothelial cell type and T cell type proved to
be insignificant [F1,13 = 0.67, P = 0.43]. In transmigra-
tion assays using lung-derived endothelial cells, two-
way ANOVA, with two between-group factors, also
revealed a significant main effect for endothelial cell
type (lung RC versus KO) [F1,15 = 27.39, P = 0.0002]
and a significant main effect for T cell type (WT ver-
sus KO) [F1,15 = 16.71, P = 0.0015]. The interaction
between EC type and T cell type proved to be insignif-
icant [F1,15 = 1.68, P = 0.22].
Similar assays were performed in a second laborato-
ry using PLP-specific T lymphoblasts isolated from
PLP-immunized SJL mice transmigrating across these
immortalized endothelioma cell lines. These endothe-
lioma lines were also noted to express equivalent levels
of ICAM-1, ICAM-2, and VCAM-1, but only WT cells
express PECAM-1 (data not shown). Migration of these
T cells across PECAM-KO endotheliomas derived from
brain (bEnd.PECAM-1.2), mesenteric lymph nodes
(mlEnd.PECAM-1.1), and lung (luEnd.PECAM-1.1)
was significantly increased in comparison with trans-
migration across WT endothelioma monolayers
(bEnd.WT) (data not shown). Interestingly, while treat-
ment of the endotheliomas with TNF-α increased sur-
face expression of ICAM-1 and VCAM-1, it did not
affect transmigration levels (data not shown) (44).
The differences in transmigration rates noted in Fig-
ures 3 and 4 likely reflect several differences in the
endothelial cells and the T lymphocytes used. The
endothelial cells used in Figure 4 were immortalized,
cloned cells, whereas low-passage endothelial cells were
used in Figure 3. Further, in other experiments T lym-
phoblasts isolated from PLP-immunized SJL mice were
used, while the T lymphocytes used in Figures 3 and 4
were C57BL/6-derived MOG-specific T lymphocytes
activated with MOG peptide and IL-2. These experi-
ments, utilizing different endothelial cells and differ-
ent T lymphocyte populations, would be expected to
yield disparate levels of transmigration. However, in all
experiments performed, transmigration rate is depend-
ent upon the presence or absence of endothelial
PECAM-1. ICAM-1 levels were found to vary modestly
on the cells. Increasing ICAM-1 and VCAM-1 expres-
sion by TNF-α treatment did not alter the transmigra-
tion rates, further supporting a role for endothelial
PECAM-1 in this process.
Vascular permeability is increased in vitro and in vivo dur-
ing development of EAE and dermal histamine challenge in
PECAM-KO mice. Migration of leukocytes across
endothelial cells has been shown to be enhanced by
vasoactive substances that disrupt endothelial junc-
tions and increase vascular permeability (52). We inves-
tigated whether endothelial junctional integrity may be
compromised in PECAM-KO monolayers. Endothe-
lioma cells derived from the lungs of PECAM-KO mice
or the same cells reconstituted with PECAM-1
(PECAM-RC) were cultured to confluence on porous
membranes as in the transmigration assays. In control
samples, Evans blue dye was added to the upper cham-
ber to confirm that the endothelial monolayers restrict-
ed its flow into the bottom chamber. Monolayers were
treated with histamine, and at various time points later,
dye was added. The dye that diffused into the lower
wells was collected and measured spectrophotometri-
cally (Figure 5). At 30 seconds after histamine exposure,
dye flowed freely across either the PECAM-KO or
PECAM-RC endothelial layers into the bottom cham-
bers. Over the next 10–15 minutes the monolayers
became increasingly impermeable to the dye. The rate
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Figure 3
Endothelial cells derived from PECAM-KO mice support increased
transmigration of MOG-specific T cells. (a and b) FACS analyses of
microvascular endothelial cells derived from WT (a; PECAM-1+, 
VE-cadherin+) and KO (b; PECAM-1–, VE-cadherin+) mice. These cells
were used for in vitro transendothelial migration assays of activated
MOG-specific T cells. (c) PECAM-KO endothelial cells supported a
31% increase in transmigration compared with WT endothelial cells
(P ≤ 0.0001, n = 8), regardless of expression of PECAM-1 by the T
cells. Endo, endothelium.
at which the endothelium became impermeable was
faster for the PECAM-RC monolayer, and the barrier of
these cells was completely restored by 15 minutes after
histamine challenge. The PECAM-KO endothelial layer
remained significantly permeable to the dye up to 20
minutes. The differences in the mean values among the
groups (RC and KO lung endothelia) are greater than
would be expected by chance (F = 5.67, P < 5.4 × 10–5).
An all-pairwise multiple comparison procedure result-
ed in significant differences between the two groups
from 2 through 15 minutes.
We next assessed the integrity of CNS vasculature in
vivo using an Evans blue vital dye permeability assay. At
various days after immunization with MOG peptide to
induce EAE, dye was injected retro-orbitally and mice
were perfused with PBS to clear it from the vasculature.
The dye that had extravasated into the brain tissue was
extracted and measured (Figure 6a). At early time points
after immunization, the CNS vasculature of both WT
and PECAM-KO mice was impermeable to dye. By day 6,
the vasculature became permeable to the dye, indicating
a breach of integrity of the endothelial cell barrier. The
brains of the PECAM-KO group exhibited a twofold
higher average PI compared with the WT group, and
there was a delay in the restoration of vascular integrity
in PECAM-KO mice. The vasculature of WT mice became
impermeable to the dye by day 12, while the permeabili-
ty barrier in the PECAM-KO mice was not restored until
day 24. The differences in the mean values among the
groups (WT and KO mice) are greater than would be
expected by chance (F = 17.9, P < 2.9 × 10–7). An all-pair-
wise multiple comparison procedure resulted in signifi-
cant differences between the two groups at days 6 and 12.
Skin vessel permeability was unaffected in both WT and
PECAM-KO mice during the course of EAE, illustrating
specificity of the response (Figure 6b) (F = 0.196, P < 0.82).
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Figure 4
Immortalized endothelial cells derived from PECAM-KO mice sup-
port increased transmigration of MOG-specific T cells. (a and b)
FACS analysis of immortalized endothelial cells derived from WT and
KO brain (a) and KO lung and PECAM-reconstituted (RC) lung
microvascular endothelial cells (b), illustrating the expression of 
VE-cadherin and ICAM-1 in all four cell types, but PECAM-1 expres-
sion only in the WT and PECAM-RC cells. (c and e) In vitro adhesion
assays illustrating no differences in MOG-specific T cell adhesion to
WT, PECAM-KO, and PECAM-RC endothelioma cells. (d and f) In
vitro transmigration assays similar to those in Figure 2c were per-
formed using MOG-specific T cells transmigrating across monolay-
ers of endothelioma cell lines. Transmigration of T cells across KO
endotheliomas derived from brain and lung was consistently and sig-
nificantly increased in comparison with transmigration across WT
and PECAM-RC endotheliomas. In c and d WT T lymphocytes were
used, and in e and f KO T lymphocytes were used. n = 4.
Figure 5
PECAM-KO endothelial cells exhibit prolonged permeability changes in response to
histamine exposure in vitro. Lung-derived PECAM-KO microvascular endothelial cells
and lung-derived PECAM-KO microvascular endothelial cells transfected with and
expressing WT PECAM-1 (PECAM-RC) were cultured in confluent monolayers on
transwell membranes, and exposed to histamine. The permeability of the monolay-
ers to Evans blue dye was measured by collecting media from the lower wells and
measuring the absorbance at 650 nm. PECAM-KO endothelial cell monolayers
(squares) exhibited prolonged permeability to the dye, lasting at least 20 minutes,
while the PECAM-RC endothelial cell monolayers (diamonds) were impermeable to
the dye by 15 minutes. n = 5.
In a separate experiment, the skin vessels were chal-
lenged with histamine to increase dermal vascular per-
meability (Figure 6c). Dye was injected at various time
points following intradermal injection of histamine or
PBS, and extracted from the skin tissue. At early time
points after histamine injection (0 minutes, 2 minutes,
5 minutes), dermal vascular permeability of both the
WT and the PECAM-KO mice was increased and
dynamic. However, by 10 minutes after histamine injec-
tion, the PECAM-KO skin vasculature remained
markedly permeable to the dye, while the WT vascula-
ture became impermeable. By 15 minutes, dermal ves-
sel integrity had been restored in both groups of mice.
The differences in the mean values among the groups
(WT and KO mice) are greater than would be expected
by chance (F = 2.86, P < 0.044). An all-pairwise multiple
comparison procedure resulted in significant differ-
ences between the two groups at 10 minutes.
In Figure 6d, dye was allowed to circulate in the blood
for 45 minutes prior to vessel challenge with histamine
so that dye accumulated in the tissue from the moment
the junctions were compromised until the mice were
sacrificed. Five minutes after histamine injection, equal
amounts of dye had extravasated in both groups of
mice. However, after 15 minutes an increase in the
amount of dye extracted from the PECAM-KO mice
indicates a greater accumulation of extravasated dye in
this group. This result is consistent with the previous
experiment, in that the prolonged time required for
restoration of vascular integrity in the PECAM-KO
mice would result in a longer period of vascular per-
meability, leading to greater accumulation of dye in the
skin tissue. The dermal vessel experiments confirm the
hypothesis that the restoration of vascular integrity is
impaired in the PECAM-KO mice, which could lead to
an exacerbated inflammatory response.
Discussion
These data suggest an unexpected proinflammatory
phenotype in PECAM-KO mice during the progression
of EAE, illustrated by increased immune cell traffick-
ing into the CNS during early disease and early onset
of clinical symptoms. During EAE, peripheral blood
lymphocytes must adhere to and migrate across the
endothelial blood-brain barrier that normally restricts
their entry into the CNS. During inflammation, the
vessels become permeable to soluble inflammatory
mediators, antigen-specific T cells, and recruited
inflammatory cells. In PECAM-KO mice, re-equilibra-
tion of the blood-brain barrier was delayed, which may
account for the increased ability of leukocytes to
migrate across the blood-brain barrier.
In vitro, PECAM-KO endothelial cells supported
enhanced transendothelial migration of T cells. This
result may seem counterintuitive, given that several
reports indicate that PECAM-1 is an important con-
tributor to leukocyte transendothelial migration in
vitro (13–15) and in vivo (16–19). However, published
data show that the requirement for PECAM-1 in the
transmigration of leukocytes is not absolute. Particu-
larly, PECAM-KO mice demonstrate a transient arrest,
but not a reduction, of transendothelial migration of
neutrophils in a peritoneal inflammation model. The
authors of that report and others suggest that there
may be compensation by other adhesion molecules in
the absence of PECAM-1 (21).
Several technical differences may also explain these
apparent discrepancies. First, there are inherent differ-
ences between antibody-blocking experiments and
those carried out using PECAM-KO mice or cells. Fur-
thermore, most previous studies have examined in vitro
transmigration or in vivo models of inflammation
mediated by neutrophils or monocytes, while EAE is
initiated by antigen-specific T cells. It has been report-
ed that a T cell population that has been depleted of
PECAM-1+ cells is able to transmigrate normally (20).
In addition, PECAM-1 expression varies among differ-
ent T cell subsets, and therefore the requirement for
PECAM-1 may differ between the wide variety of T cell
subsets (naive, activated, memory, CD4+, CD8+). It is
also important to consider the acute or chronic nature
of the inflammatory response studied in the many in
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Figure 6
Challenged vessel permeability is altered in PECAM-KO mice. (a) PIs
of mouse brain tissue after induction of EAE. In the PECAM-KO
mice, there was a significant increase (twofold) in PI by day 6 after
immunization, and the vessels remained permeable for a longer peri-
od of time compared with those of WT mice (n = 3, P < 0.03). (b)
Skin vessel PI was not affected during EAE in either group of mice 
(n = 3). (c) PIs in mouse skin following dermal histamine challenge.
The vessels of the PECAM-KO mice remained markedly permeable to
dye for up to 10 minutes after histamine injection, while the vessels
of the WT mice are mostly impermeable to the dye by 10 minutes.
PIs for both groups return to base line by 15 minutes after histamine
injection (n = 3). (d) Due to the longer time period that the PECAM-
KO vessels remain “leaky” following dermal histamine challenge,
more dye accumulates in the skin tissue of the PECAM-KO mice by
15 minutes following histamine challenge than in that of WT mice 
(n = 3, *P = 0.039). S/P, status post.
vivo models. Most studies of the role of PECAM-1 in
inflammation examine in vivo models that measure
leukocyte transmigration over a short period of time
(minutes to hours), during an acute response.
Although initial trafficking of T cells into the CNS dur-
ing EAE may occur within hours, significant extrava-
sation into the CNS tissue occurs over days, and disease
progresses over weeks. The availability of the PECAM-
KO mouse will allow for continued assessment of
inflammation and cellular behavior in the complete
absence of PECAM-1.
We hypothesize a role for PECAM-1 in the restoration
of interendothelial junctional integrity following dis-
rupting stimuli, while normal, homeostatic endotheli-
um is not affected (Figures 5 and 6b). The prolonged
vascular permeability in the PECAM-KO mice could be
accounted for if PECAM-1 plays a role in re-establish-
ing intact junctions following inflammatory stimuli
and transendothelial migration of leukocytes. In turn,
disruption of endothelial cell-cell junctions has been
shown to facilitate transmigration of leukocytes (52),
which may contribute to a cycle of increased migration
and decreased junctional integrity in the PECAM-KO
mice. However, in each of our experiments, the
endothelial permeability barrier was eventually
restored, showing that the requirement for PECAM-1
at interendothelial junctions is not absolute.
Prior studies provide support for the significance of
PECAM-1 at the endothelial cell-cell junctions.
PECAM-1 is concentrated at cell contact sites in all con-
tinuous endothelial cell linings in vivo (2) and is prox-
imal to adherens junctions (53). Anti–PECAM-1 anti-
bodies have been shown to prevent endothelial cells
from developing intercellular contacts and achieving
confluence in vitro (3) and to attenuate angiogenesis in
vivo and endothelial cell tube formation in vitro (54).
Endothelial cell-cell junctions are complex structures
consisting of transmembrane proteins and a group of
submembranous proteins that link to the actin-based
cytoskeleton (55). β-Catenin, which normally associates
with the transmembrane junctional protein VE-cad-
herin, linking it to cytoskeletal proteins, was also found
to associate with PECAM-1 (54). When stimuli, such as
VEGF stimulation, induce junctional disassembly, 
β-catenin becomes a target of kinases (56). Tyrosine-
phosphorylated β-catenin dissociates from VE-cad-
herin and associates with PECAM-1 (29). The presence
of phosphorylated β-catenin and protein tyrosine
phosphatases such as SHP-2 on the same scaffolding
molecule may induce the dephosphorylation of 
β-catenin, allowing it to reassociate with VE-cadherin,
thus reassembling intact adherens junctional com-
plexes (29). Perhaps in the PECAM-KO mice, 
PECAM-1 cannot act as a reservoir for phosphorylated
β-catenin, resulting in increased cytoplasmic pools of
the phosphorylated protein, which cannot readily reas-
sociate with VE-cadherin in the junctional complex.
Ultimately, β-catenin may become dephosphorylated
by other mechanisms and resume its association with
VE-cadherin and other junctional proteins, thus even-
tually restoring integrity of the endothelial cell layer.
Further elucidation of the underlying mechanism(s) by
which PECAM-1 modulates vascular integrity will aid
in our understanding of the roles PECAM-1 plays dur-
ing inflammatory responses. Although we have not dis-
counted the possibility that signals mediated via
PECAM-1 may contribute toward the generation or
propagation of the immune response during EAE, the
impairment of dynamic vascular junctional integrity is
likely to be one of the driving forces in the early EAE
phenotype of the PECAM-KO mice.
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